^
Association details:
| Biomarker: | MAP2K1 overexpression |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll)
Published date:
03/08/2021
Excerpt:
Overexpression of MAP2K1 mutants in vitro led to increased basal and inducible pERK and resistance to idelalisib.
DOI:
10.1182/blood.2020006765
